CryoPort (CYRX) Projected to Post Quarterly Earnings on Thursday

05 Aug 2026, 01:41 by Jessica Moore · The Cerbat Gem

CryoPort (NASDAQ:CYRX – Get Free Report) is projected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect CryoPort to announce earnings of ($0.20) per share and revenue of $48.1770 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

CryoPort (NASDAQ:CYRX – Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $47.80 million during the quarter, compared to analysts’ expectations of $44.86 million. CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. On average, analysts expect CryoPort to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CryoPort Price Performance

Shares of NASDAQ:CYRX opened at $15.22 on Wednesday. CryoPort has a 1-year low of $6.69 and a 1-year high of $16.89. The stock has a market cap of $767.09 million, a P/E ratio of 11.27 and a beta of 1.89. The firm has a fifty day moving average price of $15.49 and a 200 day moving average price of $11.84.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Needham & Company LLC upped their target price on shares of CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Guggenheim upped their price objective on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Weiss Ratings upgraded shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 6th. Jefferies Financial Group set a $13.50 target price on shares of CryoPort in a report on Monday, June 8th. Finally, BTIG Research boosted their price target on shares of CryoPort from $17.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.38.

Get Our Latest Report on CryoPort

Insider Buying and Selling

In other CryoPort news, CFO Robert Stefanovich sold 169,427 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the sale, the chief financial officer directly owned 109,850 shares in the company, valued at approximately $1,787,259.50. The trade was a 60.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ramkumar Mandalam sold 23,214 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $15.44, for a total transaction of $358,424.16. Following the transaction, the director directly owned 67,894 shares in the company, valued at approximately $1,048,283.36. This trade represents a 25.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 227,641 shares of company stock valued at $3,622,515 over the last quarter. Company insiders own 9.50% of the company’s stock.

Institutional Trading of CryoPort

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC boosted its holdings in CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after buying an additional 4,375 shares in the last quarter. Creative Planning acquired a new stake in shares of CryoPort in the 2nd quarter worth approximately $96,000. Quadrature Capital Ltd purchased a new position in CryoPort in the 4th quarter valued at approximately $97,000. State of Wyoming raised its holdings in CryoPort by 30.2% during the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after purchasing an additional 3,301 shares during the last quarter. Finally, Corient Private Wealth LLC acquired a new position in CryoPort during the fourth quarter worth $113,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

About CryoPort

(Get Free Report)

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.